| Pharmaceutical Information |
| Drug Name |
Indacaterol |
| Drug ID |
BADD_D01147 |
| Description |
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed. |
| Indications and Usage |
Not Available |
| Marketing Status |
Prescription |
| ATC Code |
R03AC18 |
| DrugBank ID |
DB05039
|
| KEGG ID |
D09318
|
| MeSH ID |
C510790
|
| PubChem ID |
6918554
|
| TTD Drug ID |
D03DJL
|
| NDC Product Code |
Not Available |
| Synonyms |
indacaterol | 5-(2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1H-quinolin-2-one | QAB-149 | arcapta neohaler | Onbrez |
|
| Chemical Information |
| Molecular Formula |
C24H28N2O3 |
| CAS Registry Number |
312753-06-3 |
| SMILES |
CCC1=C(C=C2CC(CC2=C1)NCC(C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
